900.1000 -39.90 (-4.24%)
NSE Jan 16, 2026 15:31 PM
Volume: 470.2K
 

900.10
-4.24%
Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma Science Ltd.'s price crossed below 50Day SMA today
More from Strides Pharma Science Ltd.
Recommended